Johnson & Johnson has filed for FDA approval of its antidepressant nasal spray Spravato, hoping to make it the first standalone treatment for adults with treatment-resistant depression
Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances nex
The International Agency for Research on Cancer (IARC) has published a new assessment of talc’s potential to cause cancer, concluding that is it ‘probably carcinogenic’ to humans.
Johnson & Johnson and partner Legend Biotech are celebrating a big win in their efforts to expand the use of CAR-T therapy Carvykti for multiple myeloma, after showing a survival benefi
Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drug
The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh